Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The pacemakers, insulin pumps, and neurostimulators that power Medtronic鈥檚 reputation live inside millions of patients鈥攁nd inside hundreds of dense SEC documents. Product recalls, FDA approvals, and global tax disclosures can stretch a single Medtronic annual report beyond 300 pages, leaving many investors asking 鈥榳here do I find the real story?鈥�
StockTitan answers that question the moment a document hits EDGAR. Our platform ingests every Medtronic 10-K, 10-Q, 8-K, and Form 4, then deploys AI-powered summaries so Medtronic SEC filings explained simply is more than a promise. Need Medtronic insider trading Form 4 transactions or a heads-up on director buys? AG真人官方-time alerts flag Medtronic Form 4 insider transactions real-time as they occur. Prefer big-picture context? AI pulls segment revenue and margin shifts straight from the latest Medtronic quarterly earnings report 10-Q filing and packages them into concise dashboards.
Dig deeper with one click: targeted tags guide you to R&D spend, international tax notes, and safety disclosures inside the Medtronic annual report 10-K simplified. Governance questions? The Medtronic proxy statement executive compensation view highlights pay-for-performance metrics, while Medtronic 8-K material events explained keeps you ahead of recalls or FDA warnings. Whether you鈥檙e comparing cash-flow trends, tracking Medtronic executive stock transactions Form 4, or seeking a fast Medtronic earnings report filing analysis, our AI delivers the clarity you need for confident decisions鈥�understanding Medtronic SEC documents with AI has never been easier.
Medtronic (MDT) reported first-quarter fiscal 2026 operating details showing continued product-driven revenue growth across core portfolios and ongoing corporate actions. The company announced in May 2025 its intent to separate the Diabetes Operating Unit into a standalone public company, expected within 18 months. Cardiovascular net sales were up, with Cardiac Rhythm & Heart Failure rising 12%, Structural Heart & Aortic up 9%, and Coronary & Peripheral Vascular up 5%. Medical Surgical net sales were $2.1 billion, up 4% year-over-year. Research and development expense was $726 million versus $676 million a year earlier, and selling, general, and administrative expense was $2.8 billion versus $2.7 billion. The company recognized a $90 million fair-value loss on its Mozarc investment and recorded restructuring charges of $67 million. Deferred revenue was $442 million. Total debt was $28.6 billion while liquidity included $1.3 billion cash and $6.8 billion of current investments. Accrued litigation was approximately $0.2 billion; legal and tax matters remain disclosed as potentially material.
William R. Jellison, a director of Medtronic plc (MDT), reported two open-market purchases of ordinary shares. He acquired 2,500 shares on 08/22/2025 at $92.73 per share and 2,500 shares on 08/25/2025 at $92.37 per share, bringing his reported direct beneficial ownership to 5,000 shares. The filing notes the shares are held in a joint account with his spouse. The Form 4 was executed by an attorney-in-fact on 08/25/2025. No derivative transactions or dispositions are reported in this filing.
Medtronic plc (MDT) outlines FY25 operational and governance highlights in its 2025 Definitive Proxy Statement. The company reported $7.0 billion in cash flow from operations (up 4%) and $5.2 billion in free cash flow, representing a 73% conversion from non-GAAP net earnings. Medtronic returned $6.3 billion to shareholders via $3.6 billion in dividends and $2.7 billion in net share repurchases and announced a dividend increase for the 48th consecutive year. The company invested $2.7 billion in R&D, advanced an innovation pipeline with ~170 active clinical trials and ~130 regulatory approvals, and launched multiple products across portfolios. Medtronic reduced Class 1 and 2 recalls by 33% and announced intent to separate the Diabetes segment via IPO/split within 18 months.
Michael Marinaro, Executive Vice President, President MedSurg and Americas at Medtronic plc (MDT), reported a disposition of 1,052 ordinary shares on 08/20/2025. The shares were disposed at a reported price of $93.22 and the filing states this transaction represents shares withheld for payment of taxes upon vesting of previously reported restricted stock units. After the transaction, Marinaro beneficially owned 51,939 ordinary shares. The Form 4 is signed by an attorney-in-fact, Patricia Walesiewicz, dated 08/21/2025. The filing discloses only the withholding tax disposition and current beneficial ownership.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
